Scalable CAR-Macrophage Production for Immunotherapy
Immunotherapy
Next-Gen Immunotherapy: Scalable CAR-Macrophages
The CERO 3D showcases the ability to continuously produce functional CAR-macrophages at scale. These CAR-macrophages demonstrated enhanced anti-cancer activity, highlighting the potential of CERO 3D for advancing the development of effective cell-based immunotherapies.
Representative fluorescent microscopic images of the different steps of the hematopoietic differentiation of hiPSCs to iMacs.”
Reference: M. Abdin et. al. (2023) Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia, J Immunother Cancer. 2023; 11(12): e007705
Advancing Cell Therapies
The CERO 3D is capable to generate functionally relevant macrophages from iPSC-derived hematopoietic organoids. This innovative, xeno-free approach enables the efficient and continuous production of macrophages, providing a valuable model for immunomodulatory drug testing.
Reference: Ackermann et. al. (2024) Standardized generation of human iPSC-derived hematopoietic organoids and macrophages utilizing a benchtop bioreactor platform under fully defined conditions, Stem Cell Res Ther. 2024; 15: 171
Revolutionize Immunotherapy with Scalable CAR-Macrophage
Production – Request a Free Demo Today
Take immunotherapy to the next level with CERO 3D. This advanced bioreactor
system enables the continuous, xeno-free production of CAR-macrophages,
supporting efficient cell therapy development and immunomodulatory drug
testing. Generate highly functional immune cells with precision and scalability.
Optimize your cell-based immunotherapies with CERO 3D. Request a free demo
today!
Request a Free Demo